Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luxeptinib (CG-806) in Relapsed/Refractory AML or High-Risk MDS
NCT04477291Phase 1Terminated
- Sponsor
- Aptose Biosciences Inc.
- Start
- Oct 2020
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of luxeptinib in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Aptose Biosciences Inc. Primary endpoints: Incidence of treatment-emergent adverse events of CG-806, Establish a CG-806 dose that maintains a biologically active plasma concentration and 1 more. Started Oct 2020; status: terminated.
02
Drugs
luxeptinib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04477291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04477291.